Does TRICARE Cover Liraglutide?

What Is Liraglutide and Why Does Formulation Matter for TRICARE Coverage?

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist sold under two distinct brand names that carry separate FDA approvals and separate coverage pathways within TRICARE. Saxenda (liraglutide 3 mg) received FDA approval in December 2014 as an adjunct to reduced-calorie diet and exercise for chronic weight management in adults with a body-mass index of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Victoza (liraglutide up to 1.8 mg) received FDA approval in January 2010 for glycemic control in adults with type 2 diabetes and later for cardiovascular risk reduction in patients with established cardiovascular disease [2].

The distinction matters enormously for TRICARE billing. Saxenda submits under an obesity-drug benefit, which has historically received tighter scrutiny in federal health programs. Victoza submits under a diabetes-management benefit, which carries a longer coverage track record inside the Defense Health Agency formulary system.

TRICARE is administered through regional contractors, currently including Humana Military (East region) and Health Net Federal Services (West region), with the TRICARE for Life program primarily serving Medicare-eligible retirees. Each contractor interprets Defense Health Agency pharmacy benefit policies, meaning documentation requirements can vary by region even though the underlying federal policy is the same. Confirming requirements with your specific contractor before submission saves significant time.

No generic liraglutide exists in the United States as of mid-2025. The molecule's patent protection and the complexity of manufacturing peptide-based injectables have delayed biosimilar entry. Any "generic liraglutide" discussed in telehealth or compounding contexts refers to compounded liraglutide, which occupies a separate regulatory category under FDA oversight of 503A and 503B compounders [3]. TRICARE does not cover compounded liraglutide.

TRICARE Formulary Status for Liraglutide

TRICARE operates a four-tier pharmacy benefit structure. Most brand-name drugs without a generic equivalent land on Tier 3 (non-formulary brand) unless they receive specific formulary placement through the Defense Health Agency's Pharmacy and Therapeutics Committee review. Both Saxenda and Victoza currently sit in a non-preferred or non-formulary tier for the majority of TRICARE beneficiaries, though Victoza has moved to preferred status in some contract periods given its long tenure and established cardiovascular outcome data from the LEADER trial [4].

The practical cost consequence for a non-formulary placement through a TRICARE retail pharmacy is a 20 to 25 percent cost-share after deductible under TRICARE Prime, and up to 50 percent under TRICARE Select for non-network pharmacies. At the $1,349 monthly list price of Saxenda, a 25 percent cost-share reaches roughly $337 per month, still a substantial out-of-pocket figure for many military families.

Through the TRICARE Mail Order Pharmacy (TMOP) program, non-formulary drugs that have received prior authorization can be dispensed at a 90-day supply with a slightly lower cost-share structure than retail. Beneficiaries who refill regularly should ask their prescribing physician to write a 90-day supply once the PA is secured.

The Defense Health Agency publishes an updated formulary search tool at health.mil. Checking the current tier placement before your appointment prevents confusion about what documentation the contractor will require.

Prior Authorization Criteria for Liraglutide Under TRICARE

Prior authorization is the central obstacle for most TRICARE beneficiaries seeking liraglutide. The criteria differ between the two indications.

For Saxenda (obesity indication):

TRICARE contractors generally require all of the following before approving Saxenda:

1. A documented BMI of 30 kg/m² or greater, or BMI of 27 kg/m² with at least one documented obesity-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or type 2 diabetes).
2. Evidence of a minimum 12-week structured lifestyle intervention that failed to produce clinically meaningful weight loss, typically defined as less than 5 percent body weight reduction.
3. Absence of personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, per the FDA boxed warning on the Saxenda label [1].
4. Confirmation that the prescriber is a physician or advanced practice provider with documentation of an obesity-focused treatment plan.

Some contractors also require documentation that the patient has been counseled about the need for continued lifestyle modification alongside pharmacotherapy, consistent with the American Association of Clinical Endocrinology (AACE) 2023 Obesity Algorithm, which states: "Pharmacological therapy for obesity should always be combined with lifestyle intervention and not used as a standalone approach" [5].

For Victoza (type 2 diabetes indication):

The prior-authorization bar for Victoza is somewhat lower. Contractors typically require:

1. A confirmed type 2 diabetes diagnosis with HbA1c at or above 7.0 percent on at least one measurement within the prior 12 months.
2. Documentation of an adequate trial of metformin (at least 500 mg twice daily for a minimum of 90 days) unless metformin is contraindicated or not tolerated.
3. For the cardiovascular risk-reduction indication, documentation of established atherosclerotic cardiovascular disease (prior MI, stroke, or peripheral arterial disease).

The prescribing physician should prepare a PA packet that includes the most recent lab results, visit notes documenting treatment history, and a letter of medical necessity that explicitly addresses each criterion. A well-prepared packet submitted by an experienced PA coordinator reduces approval wait time from the typical 7 to 14 business days toward the 3 to 5 day range.

Step Therapy Requirements for Liraglutide

Step therapy is a coverage mechanism that requires a patient to try and fail one or more lower-cost or preferred medications before the insurer will approve a more expensive option. TRICARE applies step therapy to GLP-1 receptor agonists with variable rigor depending on indication and contractor.

Obesity indication step therapy: TRICARE contractors have, in many cases, required documented failure of phentermine/topiramate (Qsymia) or bupropion/naltrexone (Contrave) before approving Saxenda. Both of those agents carry significantly lower cost-share obligations for beneficiaries, which is the stated rationale. The 12-week lifestyle intervention requirement described in the PA criteria above functions as a de facto first step even before oral medications.

Type 2 diabetes step therapy: Metformin remains the near-universal first step. After metformin, TRICARE contractors vary on whether they require a sulfonylurea or SGLT-2 inhibitor trial before Victoza. Beneficiaries whose physicians document that a sulfonylurea is contraindicated (e.g., significant hypoglycemia risk, eGFR limitations) or that the patient has established cardiovascular disease making a GLP-1 the preferred second agent per American Diabetes Association 2024 Standards of Care guidance [6] can often bypass the sulfonylurea step.

Step therapy waiver requests should be submitted simultaneously with the initial PA request when there is a clinical reason to skip a step. Waiting for a denial before requesting a waiver adds weeks to the process.

The HealthRX clinical team has reviewed TRICARE PA packets across both obesity and diabetes indications. The single most common reason for outright denial, rather than a step-therapy redirect, is incomplete documentation of the timeline of prior treatment. Specifically, contractors need to see dated chart notes showing the start and end of the lifestyle intervention period and the weight or HbA1c values at each point. A single note stating "patient tried diet and exercise without success" does not meet the evidentiary standard that most TRICARE contractors enforce.

How to Appeal a TRICARE Denial for Liraglutide

A denied PA for liraglutide is not the end of the road. TRICARE provides a three-level internal appeals process before external review becomes available.

Level 1: Reconsideration

File within 90 days of the denial notice. Submit to the same contractor that issued the denial. Include any clinical documentation not included in the original PA, a letter of medical necessity from the treating physician, and relevant peer-reviewed literature. The SCALE Obesity trial (N=3,731), published in the New England Journal of Medicine in 2015, demonstrated that liraglutide 3 mg produced 8.4 percent mean body-weight loss at 56 weeks compared to 2.8 percent with placebo (P<0.001), with 63.2 percent of participants achieving at least 5 percent weight loss [7]. Citing this trial with the full citation in the appeal letter establishes clinical grounding that reviewers recognize.

The contractor must respond within 30 days for non-urgent appeals or 72 hours for urgent clinical appeals.

Level 2: Formal Review

If the reconsideration is denied, request a formal review from the TRICARE contractor's appeals department. At this stage, an independent medical reviewer within the contractor organization evaluates the case. The physician should request a peer-to-peer phone review with the contractor's medical director. These calls routinely change outcomes. The peer-to-peer typically takes 15 to 20 minutes and gives the treating physician the opportunity to explain clinical nuances that do not translate well into written documentation.

Level 3: External Independent Review

If the formal review is denied, request an external review through the TRICARE contractor's External Independent Review process. An organization outside of TRICARE reviews the case with no financial stake in the outcome. External reviews reverse contractor decisions in a meaningful proportion of GLP-1 related cases when the appeal includes complete documentation and current evidence-based guidelines.

Beyond the three internal levels, beneficiaries may escalate to the Defense Health Agency's beneficiary assistance programs or, in cases of suspected procedural error, contact their Congressional representative's constituent services office. Congressional inquiries do not guarantee a different outcome but do prompt documented contractor responses on a compressed timeline.

Cost-Sharing Options and What Is Not Allowed

TRICARE cost-share structures:

Under TRICARE Prime, the typical cost-share for a non-formulary prior-authorized drug is 20 percent after the annual deductible ($150 individual / $300 family for most active-duty family members). Under TRICARE Select, the cost-share rises to 25 percent in-network and 50 percent out-of-network.

Manufacturer savings cards: a federal prohibition:

Novo Nordisk, which manufactures both Saxenda and Victoza, offers savings cards that can reduce out-of-pocket costs for commercially insured patients to as low as $25 per month. These cards are explicitly prohibited from use with any federal health program, including TRICARE, Medicare, Medicaid, and CHAMPVA. Using a manufacturer savings card while enrolled in TRICARE constitutes a violation of the federal Anti-Kickback Statute. There are no exceptions. Any telehealth or pharmacy that suggests otherwise is providing incorrect advice.

Legitimate cost-reduction pathways under TRICARE:

1. Novo Nordisk's patient assistance programs (NovoCare) are available for TRICARE beneficiaries who meet income criteria, as these are distinct from savings cards and operate outside the insurance billing pathway. Applications are at novonordisk-us.com.
2. The TRICARE Mail Order Pharmacy (TMOP) reduces the per-unit cost-share on approved non-formulary drugs compared to retail dispensing.
3. Requesting a formulary exception: a physician can submit a formulary exception request simultaneously with the PA request to seek preferred-tier placement based on medical necessity. Approval moves the drug to a lower cost-share tier for that beneficiary.

Covered Alternatives to Liraglutide Under TRICARE

TRICARE covers several other GLP-1 and GIP/GLP-1 receptor agonists with prior authorization. Understanding where liraglutide sits relative to these agents helps both prescribers and patients make informed decisions before starting the PA process.

Semaglutide 2.4 mg (Wegovy) has become the most-cited alternative for obesity. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9 percent mean weight loss at 68 weeks versus 2.4 percent with placebo [8]. TRICARE covers Wegovy with prior authorization under the same obesity-indication criteria as Saxenda, and many contractors have shifted toward Wegovy as the preferred GLP-1 for obesity given its superior weight-loss data.

Tirzepatide (Zepbound for obesity, Mounjaro for T2D) is also covered with prior authorization. The SURMOUNT-1 trial (N=2,539) showed that tirzepatide 15 mg produced 20.9 percent mean weight loss at 72 weeks versus 3.1 percent with placebo [9].

Exenatide extended-release (Bydureon BCise) and dulaglutide (Trulicity) are preferred options for type 2 diabetes in some TRICARE formularies because of their longer on-formulary history and lower cost-share tiers.

For type 2 diabetes specifically, semaglutide 0.5 or 1 mg (Ozempic) is frequently the GLP-1 of first choice in the TRICARE formulary for that indication, given cardiovascular outcome data from the SUSTAIN-6 trial [10] and active preferred-formulary status in several contractor periods.

Prescribers should check the current Defense Health Agency formulary before writing the prescription. Selecting a preferred-formulary GLP-1 when clinically equivalent can save the patient months of PA and step-therapy navigation.

Documentation Checklist for Prescribers

The following documentation should be assembled before submitting any TRICARE PA for liraglutide. Missing items are the leading cause of avoidable delays.

For Saxenda (obesity):

• Current weight, height, and calculated BMI with the date of measurement
• ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.09 (other obesity) with any applicable comorbidity codes
• At least two visit notes spanning a 12-week period documenting a structured behavioral weight loss program with weight values at each visit
• For BMI 27 to 29.9: documentation of the qualifying comorbidity with its own ICD-10 code and clinical confirmation
• Signed attestation that the patient has no personal or family history of MTC or MEN-2
• Letter of medical necessity addressing each PA criterion by name

For Victoza (type 2 diabetes):

• HbA1c result with lab date within the prior 12 months
• ICD-10 code E11.65 (type 2 diabetes with hyperglycemia) or appropriate sub-code
• Documented metformin trial with dose and duration, or explicit contraindication documentation
• For cardiovascular indication: cardiology or primary care notes confirming ASCVD diagnosis
• Prescriber NPI and DEA number on the PA form (omission of these causes automatic pend status at many contractors)

TRICARE's standard PA form is available through each contractor's provider portal. Submitting electronically through the portal reduces processing time compared to fax submission and creates a date-stamped record useful for tracking the 30-day response deadline.

Practical Timeline: What to Expect

A typical TRICARE liraglutide prior-authorization cycle from complete submission to a dispensed prescription runs 10 to 21 calendar days when the documentation is complete. The following sequence applies to most beneficiaries.

Days 1 to 2: Prescriber submits PA electronically with complete documentation packet. Days 3 to 7: Contractor's pharmacy benefit manager performs initial review. Day 7 to 10: Approval, denial, or request for additional information is issued. If additional information is requested: a 5 to 7 day extension is typical. If denied: Level 1 reconsideration can be filed immediately; peer-to-peer should be requested within 24 hours of the denial letter.

Patients who are in urgent clinical circumstances (for example, a type 2 diabetic with HbA1c above 10 percent and cardiovascular disease) should request an expedited PA review. Contractors are required to respond to expedited requests within 72 hours. The treating physician must document in writing why waiting the standard timeframe would seriously jeopardize the patient's health.